Elkhodari
Hamza Elkhodari, individually and on behalf of all others similarly situated v. Unicycive Therapeutics, Inc., et al.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 HAMZA ELKHODARI, individually and on Case No. 25-cv-06923-JD behalf of all others similarly situated, 8 Plaintiffs, ORDER RE LEAD PLAINTIFF AND LEAD COUNSEL v. 10 UNICYCIVE THERAPEUTICS, INC., et al., Defendants.
13 This putative shareholder class action alleges securities fraud claims against defendant 14 Unicycive Therapeutics, Inc. and its officers. Dkt. No. 1. Two shareholders initially asked to be 15 appointed lead plaintiff, Dkt. Nos. 11, 14, but one withdrew, Dkt. No. 22. Andrew Coleman is the 16 only applicant to be lead plaintiff, without opposition by any party. Coleman’s motion is suitable 17 for decision without oral argument, and the hearing set for November 20, 2025, is vacated. 18 Coleman is appointed lead plaintiff. The proposed appointment of Pomerantz LLP as lead counsel 19 is deferred pending further order.
I. APPOINTMENT OF LEAD PLAINTIFF
21 The Court has discussed in other orders the three-step process for appointing a lead 22 plaintiff under the Private Securities…